TG Therapeutics (TG Therapeutics) Total Inventories : $77.7 Mil (As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is TG Therapeutics Total Inventories?

TG Therapeutics's total inventories for the quarter that ended in Mar. 2024 was $77.7 Mil. TG Therapeutics's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $58.8 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. TG Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.54.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. TG Therapeutics's Days Inventory for the three months ended in Mar. 2024 was 985.64.

Inventory Turnover measures how fast the company turns over its inventory within a year. TG Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.09.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. TG Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.93.

TG Therapeutics Total Inventories Historical Data

The historical data trend for TG Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Total Inventories Chart

TG Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

39.82

TG Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															27.22	30.23	33.55	39.82	77.72

TG Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

TG Therapeutics (NAS:TGTX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

TG Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(209.785	+	0.75 * 64.982	+	0.5 * 77.719	-	213.214
-	0	-	0)	/	154.566
=	0.54

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

TG Therapeutics's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	58.771	/	5.441	*	365 / 4
	=	985.64

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

TG Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	5.441	/	58.771
	=	0.09

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

TG Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	58.771	/	63.474
	=	0.93

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

TG Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics (TG Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (NAS:TGTX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

NKB2:Germany NKB2:Germany

Address

3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

Executives

Laurence N Charney	director	MARVEL ENTERTAINMENT, INC., 417 FIFTH AVENUE, NEW YORK NY 10016
Sean A Power	officer: CFO, Secretary and Treasurer	787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Michael S Weiss	director, officer: CEO and President	750 LEXINGTON AVE, NEW YORK NY 10022
Sagar Lonial	director	C/O TG THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Yann Echelard	director	C/O LFB BIOTECHNOLOGIES, S.A.S., 3, AVENUE DES TROPIQUES LES ULIS, COURTABOEUF I0 91958
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Daniel Hume	director	3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
William James Kennedy	director	C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Lfb Biotechnologies S.a.s.u.	10 percent owner	3 AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91958
Mark Schoenebaum	director	787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK NY 10019
Opus Point Partners, Llc	10 percent owner	787 7TH AVENUE, 48TH FLOOR, NEW YORK NY 10019